TABLE 1.
Baseline characteristics of all eligible participants.
| Variables | Total | 10-year ASCVD risk (%) |
||
| <5 | 5–<10 | ≥10 | ||
| N | 3,595 | 1,983 | 927 | 685 |
| Males, n (%) | 1,198 (33.32%) | 201 (10.14%) | 464 (50.05%) | 533 (77.81%) |
| Age (years) | 55.05 ± 7.60 | 51.56 ± 5.49 | 57.20 ± 6.46 | 62.22 ± 8.18 |
| Waist (cm) | 81.95 ± 8.40 | 78.77 ± 7.58 | 85.11 ± 7.93 | 86.91 ± 7.15 |
| Body mass index (kg/m2) | 25.85 ± 3.27 | 25.19 ± 3.14 | 26.64 ± 3.41 | 26.67 ± 3.04 |
| Current smoking, n (%) | 630 (17.52%) | 115 (5.80%) | 267 (28.80%) | 248 (36.20%) |
| Current drinking, n (%) | 837 (23.29%) | 257 (12.97%) | 311 (33.55%) | 269 (39.27%) |
| Systolic blood pressure (mmHg) | 131.35 ± 15.68 | 124.60 ± 12.71 | 135.43 ± 13.46 | 145.37 ± 15.03 |
| Diastolic blood pressure (mmHg) | 75.00 ± 9.55 | 72.86 ± 8.49 | 76.62 ± 9.22 | 78.98 ± 11.06 |
| Total cholesterol (mmol/L) | 5.34 ± 0.99 | 5.36 ± 0.96 | 5.37 ± 1.04 | 5.27 ± 0.99 |
| High-density lipoprotein (mmol/L) | 1.46 ± 0.38 | 1.56 ± 0.38 | 1.37 ± 0.34 | 1.28 ± 0.32 |
| eGFR (ml/min/1.73 m2) | 96.50 ± 11.72 | 100.20 ± 9.74 | 94.19 ± 11.47 | 88.90 ± 12.81 |
| Combined diseases, n (%) | ||||
| Hypertension | 1,467 (40.81%) | 438 (22.09%) | 471 (50.81%) | 558 (81.46%) |
| Diabetes | 678 (18.86%) | 119 (6.00%) | 243 (26.21%) | 316 (46.13%) |
| Dyslipidemia | 2,477 (68.90%) | 1,292 (65.15%) | 686 (74.00%) | 499 (72.85%) |
| Medications, n (%) | ||||
| Antihypertensive | 860 (24.23%) | 242 (12.39%) | 282 (30.79%) | 336 (49.34%) |
| Hypoglycemic | 235 (6.55%) | 37 (1.87%) | 89 (9.64%) | 109 (15.96%) |
| Lipid-lowering | 242 (6.86%) | 96 (4.93%) | 85 (9.40%) | 61 (9.01%) |
| 10-year ASCVD risk, n (%) | 4.35 (2.24–8.44) | 2.43 (1.50–3.49) | 6.98 (5.95–8.27) | 14.19 (11.81–18.50) |
Data are expressed as mean ± standard deviation or median (interquartile range) as appropriate for continuous variables and n (%) for categorical variables.
ASCVD, atherosclerotic cardiovascular disease; ABI, ankle–brachial index; eGFR, estimated glomerular filtration rate.